Sugi Predict

Sugi Predict / Targets / FYN

FYN

Tyrosine-protein kinase Fyn · P06241 · FYN on Sugi Atlas →

277,621 patent compounds predicted against FYN, 201,318 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL60289 SCHEMBL60289 0.48 4/20
SCHEMBL58735 SCHEMBL58735 0.47 4/20
Sulconazole Sulconazole (SCHEMBL34761) 1.00 3/20
Sulconazole Sulconazole (SCHEMBL34762) 1.00 3/20
SCHEMBL58313 SCHEMBL58313 0.59 3/20
SCHEMBL58543 SCHEMBL58543 0.57 3/20
SCHEMBL60464 SCHEMBL60464 0.57 3/20
SCHEMBL22320 SCHEMBL22320 0.56 3/20
SCHEMBL58550 SCHEMBL58550 0.55 3/20
SCHEMBL20941 SCHEMBL20941 0.51 3/20
SCHEMBL59547 SCHEMBL59547 0.49 3/20
SCHEMBL58496 SCHEMBL58496 0.44 3/20
SCHEMBL59133 SCHEMBL59133 0.43 3/20
SCHEMBL19783 SCHEMBL19783 0.42 3/20
SCHEMBL9255 SCHEMBL9255 0.42 3/20
SCHEMBL19518 SCHEMBL19518 0.42 3/20
SCHEMBL5133 SCHEMBL5133 0.37 3/20
Miconazole Miconazole (SCHEMBL2866) 1.00 2/20
(R)-Miconazole (R)-Miconazole (SCHEMBL2867) 1.00 2/20
Doxorubicin Doxorubicin (SCHEMBL3243) 1.00 2/20

Clinical trials — most relevant to FYN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment PHASE3UNKNOWN
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma PHASE2COMPLETED
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer PHASE2COMPLETED
Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) PHASE1/PHASE2UNKNOWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission PHASE2NOT_YET_RECRUITING
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Fostamatinib for Hospitalized Adults With COVID-19 PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases PHASE1COMPLETED
A Clinical Study to Evaluate SM17 in Healthy Participants PHASE1COMPLETED
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors PHASE1COMPLETED
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma PHASE1UNKNOWN
A Study on the Safety, Tolerability and Pharmacokinetics of WS-0101 Tablets in Chinese Healthy Subjects PHASE1COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) PHASE1COMPLETED
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment PHASE1COMPLETED
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants PHASE1NOT_YET_RECRUITING
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas nanNOT_YET_RECRUITING
RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FYN binder may also engage these)

ProteinNameSimilarity
Q62844 — 1.000 Q62844 →
A1Y2K1 — 1.000 A1Y2K1 →
Q6EWH2 — 1.000 Q6EWH2 →
P10936 — 1.000 P10936 →
P39688 — 1.000 P39688 →
P00527 — 1.000 P00527 →
Q05876 — 1.000 Q05876 →
A0JNB0 — 1.000 A0JNB0 →
A1A5H8 — 1.000 A1A5H8 →
F1LM93 — 1.000 F1LM93 →
FGR Tyrosine-protein kinase Fgr 1.000 landscape →
Q02977 — 1.000 Q02977 →
P06240 — 1.000 P06240 →
LYN Tyrosine-protein kinase Lyn 1.000 landscape →
P09324 — 0.999 P09324 →
Q28923 — 0.999 Q28923 →
P14234 — 0.999 P14234 →
P13406 — 0.999 P13406 →
P27446 — 0.998 P27446 →
P13116 — 0.998 P13116 →
P27447 — 0.998 P27447 →
Q5PXS1 — 0.998 Q5PXS1 →
Q9V9J3 — 0.997 Q9V9J3 →
Q01621 — 0.997 Q01621 →
P25911 — 0.997 P25911 →
Q04736 — 0.997 Q04736 →
P00526 — 0.996 P00526 →
Q6P6U0 — 0.996 Q6P6U0 →
P13115 — 0.996 P13115 →
F1RDG9 — 0.996 F1RDG9 →